LENVATINIB



Lenvima


Indication:


This medication is used to treat thyroid cancer (differentiated type) that is progressing and can no longer be treated with radioactive iodine. Lenvima (Lenvatinib) belongs to a class of drugs known as tyrosine kinase inhibitors. It works by slowing or stopping the growth of cancer cells.



Brand name:Lenvima

Active Ingeridents:Lenvatinib

Company Name:Eisai

Package:30 capsules

Strength :4mg

Mechanism of action:


Lenvima (Lenvatinib) is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvima (Lenvatinib)also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1,2,3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.


Dosage and Administration:


  • Lenvima (Lenvatinib) is a pill, taken by mouth, once daily. It can be taken with or without food.
  • Take Lenvima (Lenvatinib) exactly as prescribed.
  • Swallow Lenvima (Lenvatinib) capsules whole. Do not crush, dissolve or open capsules.
  • If you miss a dose, take it as soon as you remember. If your next dose is within 12 hours, skip the missed dose and take the next dose at your regular time.
  • The amount of Lenvima (Lenvatinib) that you will receive depends on many factors, your general health or other health problems, and the type of cancer or condition being treated.
  • Dose modifications are often made so it is important to let your healthcare provider know of any side effects.

Side effects:


Dry mouth, hoarseness, nose bleeds, tiredness, weight loss, headache, muscle/joint pain, trouble sleeping, and change in taste, diarrhea, and constipation, upset stomach, nausea, vomiting, or loss of appetite may occur. Nausea and vomiting can be severe. In some cases, your doctor may prescribe medication to prevent or relieve nausea and vomiting. Eating several small meals, not eating before treatment, or limiting activity may help lessen some of these effects. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.


Store:


Store at room temperature, away from heat, moisture, Keep out of the reach of children. Do not keep outdated medicine or medicine no longer needed.







Precaution:


Before taking lenvatinib, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.


WARNING:


Lenvima (Lenvatinib) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.




Lenvima



Indication:


This medication is used to treat thyroid cancer (differentiated type) that is progressing and can no longer be treated with radioactive iodine. Lenvima (Lenvatinib) belongs to a class of drugs known as tyrosine kinase inhibitors. It works by slowing or stopping the growth of cancer cells.



Brand name:Lenvima

Active Ingeridents:Lenvatinib

Company Name:Eisai

Package:Five 10mg capsules and ten 4mg capsules per card

Strength :18mg

Mechanism of action:


Lenvima (Lenvatinib) is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvima (Lenvatinib)also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1,2,3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.


Dosage and Administration:


  • Lenvima (Lenvatinib) is a pill, taken by mouth, once daily. It can be taken with or without food.
  • Take Lenvima (Lenvatinib) exactly as prescribed.
  • Swallow Lenvima (Lenvatinib) capsules whole. Do not crush, dissolve or open capsules.
  • If you miss a dose, take it as soon as you remember. If your next dose is within 12 hours, skip the missed dose and take the next dose at your regular time.
  • The amount of Lenvima (Lenvatinib) that you will receive depends on many factors, your general health or other health problems, and the type of cancer or condition being treated.
  • Dose modifications are often made so it is important to let your healthcare provider know of any side effects.

Store:


Store at room temperature, away from heat, moisture, Keep out of the reach of children. Do not keep outdated medicine or medicine no longer needed.


Side effects:


Dry mouth, hoarseness, nose bleeds, tiredness, weight loss, headache, muscle/joint pain, trouble sleeping, and change in taste, diarrhea, and constipation, upset stomach, nausea, vomiting, or loss of appetite may occur. Nausea and vomiting can be severe. In some cases, your doctor may prescribe medication to prevent or relieve nausea and vomiting. Eating several small meals, not eating before treatment, or limiting activity may help lessen some of these effects. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.


Precaution:


Before taking lenvatinib, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.











WARNING:


Lenvima (Lenvatinib) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.